Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
16 mars 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
BioMed X Launches New T Cell Immunology Discovery Platform
14 févr. 2023 06h00 HE
|
BioMed X Institute (990552)
HEIDELBERG, Germany, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BioMed X announced today the launch of its new immunology discovery platform that will allow for the accurate and fast identification of target...
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
30 janv. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Explora BioLabs Launches Preclinical Vivarium Model in Seattle
24 janv. 2022 11h00 HE
|
Explora BioLabs
SEATTLE, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Explora BioLabs, the national provider of industry-leading preclinical vivarium research space and management services headquartered in San Diego, recently...
Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia
26 mars 2018 10h00 HE
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 26, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. and the Abramson Cancer Center of the University of Pennsylvania announced today the presentation of new preclinical...
Biothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of Action
13 nov. 2017 09h30 HE
|
Biothera Pharmaceuticals, Inc.
Reduces expression of IDO, a potent suppressor of an anti-cancer T cell response Supplementation with IVIG boosts biomarker levels, restoring Imprime-driven pharmacodynamic responses EAGAN, Minn.,...
Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing
30 oct. 2017 09h00 HE
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today the presentation of new preclinical findings showing that the Company’s Phase 2 cancer immunotherapy...
Biothera Announces Three Presentations at Upcoming American Association for Cancer Research (AACR) Annual Meeting
27 mars 2017 11h00 HE
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., March 27, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR)...